Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort.

Daniel S RooksOlivier PetricoulJens PraestgaardMichael BartlettDidier LaurentRonenn Roubenoff

Published in: Journal of cachexia, sarcopenia and muscle (2020)

Bimagrumab was safe and well tolerated and demonstrated similar PK in older and obese adults. A single dose of bimagrumab rapidly increased TMV and LBM and decreased body adiposity in older adults. Muscle hypertrophy and fat loss were sustained with extended drug exposure.

Keyphrases

body composition
physical activity
adipose tissue
community dwelling
middle aged
weight loss
resistance training
metabolic syndrome
type diabetes
insulin resistance
bone mineral density
skeletal muscle
obese patients
bariatric surgery
body mass index
adverse drug
electronic health record
drug induced